Sofia Heigis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this e

Oncopeptalks on the company's rights issue March 13, 2024 Listen to Sofia Heigis, CEO, and Henrik Bergentoft, CFO, talk about why Oncopeptides is carrying out a...

Oncopeptides announces successful price negotiations for Pepaxti in GermanyStockholm – September 26, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that following negotiations between Oncopeptides and the German Federal Joint Committee National Ass...

Oncopeptides announces successful price negotiations for Pepaxti in Germany Stockholm - September 26, 2023 - Oncopeptides AB , a biotech company focused on difficult-to-treat...

Oncopeptides launches Oncopeptalks with a fireside chat featuring CEO Sofia Heigis September 20, 2023 Join David Augustsson, Director, Corporate Affairs at...